⁃ A. Children, Adolescents, Young adults (ages 6 months to ≤39 years) with the following diseases may be eligible:

⁃ i. ALL

• ALL high risk including one or more of the following: (t(9;22) or 11q23 chromosomal abnormality, primary induction failure (≤15% blasts at time of registration), mixed phenotype acute leukemia (MPAL), persistent MRD (≥0.01% by flow or persistent abnormal karyotype detected by cytogenetics) or hypodiploidy (≤44 chromosomes)) in first remission

• ALL in second remission and beyond

⁃ ii. AML

• History of AML induction/reinduction Failure (≤15% blasts at time of registration)

• AML in CR1 with poor cytogenetics (i.e., 12p, 5a, -7, FLT3 mutation/duplication, t(9;11) and others)

• AML with persistent minimal residual disease (MRD) in CR1(≥0.01% on flow or persistent abnormal karyotype detected by cytogenetics)

• AML CR2 or beyond

• AML in refractory relapse but ≤15% bone marrow leukemia blasts

• Therapy-related AML

⁃ iii. Juvenile MyeloMonocytic Leukemia (JMML)

• JMML in CR1 without CBL mutation

• JMML with recurrence of disease with or without CBL mutation

• JMML CR2 or beyond

⁃ iv. Chronic Myeloid Leukemia (CML)

⁃ 1\. CML in CR with regard to blast crisis

⁃ v. High Risk Myelodysplastic syndrome (MDS)

⁃ vi. Lymphoma: Hodgkin (HL) or Non-Hodgkin (NHL)

• HL or NHL with a history of induction failure

• HL or NHL in PR1 or PR2

• HL or NHL in CR2 or subsequent remission

⁃ B. Subjects must not have more than one active malignancy at the time of enrollment (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen \[as determined by the treating physician and approved by the PI\] may be included).

⁃ C. HLA-matched (5-6/6) sibling donor, matched (8-10/10) unrelated donor available for stem cell donation, haplo-identical related donor (at least one full haplotype must be matched).

⁃ D. Karnofsky or Lansky score ≥60% at the time of enrollment. Karnofsky scores must be used for patients \>16 years of age and Lansky scores for patients ≤16 years of age.

⁃ E. Adequate organ function (within 4 weeks of initiation of preparative regimen), defined as:

⁃ i. Pulmonary: FEV1, FVC, and corrected DLCO must all be ≥ 60% of predicted by pulmonary function tests (PFTs). For children who are unable to perform for PFTs due to age, the criteria are: no evidence of dyspnea at rest and no need for supplemental oxygen.

⁃ ii. Renal: Creatinine clearance or radioisotope GFR ≥60 mL/min/1.73 m2 or a serum creatinine based on age/gender

⁃ iii. Cardiac: Shortening fraction of ≥ 27% by echocardiogram) or ejection fraction of ≥ 50% by echocardiogram or radionuclide scan (MUGA).

⁃ iv. Hepatic: SGOT (AST) or SGPT (ALT) \< 5 x upper limit of normal (ULN) for age. Conjugated bilirubin \< 2.5 mg/dL, unless attributable to Gilbert's Syndrome.

⁃ F. Written informed consent obtained from the subject or guardian and the subject agrees to comply with all the study-related procedures.

⁃ G. Subjects of childbearing potential (SOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 8 weeks after the last dose of study drug to minimize the risk of pregnancy.

⁃ H. Subjects with partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 8 weeks following the last dose of study drug.